Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".

Enriqueta Felip, Heather A Wakelee, Chenqi Fu, Yu Deng, Fanny Masson, Barbara Gitlitz